Menu

Managing the Risks Associated with Postoperative Residual Neuromuscular Blockade to Improve the Patient Experience

  • Claim Credits by 10/18/2021
  • Online Activity
Credits Available: CME, Quality Improvement (Part 4)
Improve your knowledge and competence in the management of patients in the intraoperative and postoperative care arena and discover how to make a positive impact on a patient being treated with neuromuscular blockers.  This individually paced...  Read More +



Item Details

The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Anesthesiologists designates this enduring activity for a maximum of 10.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification in Anesthesiology™ program and MOCA® are registered trademarks of The American Board of Anesthesiology®. MOCA 2.0® is a trademark of the American Board of Anesthesiology®.
 
This activity contributes to the Part IV: Improvement in Medical Practice requirement of the American Board of Anesthesiology’s (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0™. Up to 7.5 points for completion of Module 3.

After the completion of this course, you will be able to:

  • Utilize database studies and clinical studies in finding the clinical implications of postoperative residual neuromuscular block.
  • Define important neuromuscular blockade key terms related to postoperative residual weakness.
  • Explain the scope of postoperative residual weakness by reviewing recent RECITE trials in China, Canada and the U.S
  • Identify three strategies to avoid postoperative residual weakness
  • Define deep neuromuscular blockade
  • Explain how to monitor deep block
  • Employ a proposed strategy for the choice of pharmacological reversal agent and appropriate dosing
All members of the anesthesia care team. 
Glenn Murphy, M.D; J. Ross Renew, M.D.; Stephan Thilen, M.D.
The American Society of Anesthesiologists remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the American Society of Anesthesiologists to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the American Society of Anesthesiologists to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair to ensure that such situations are properly evaluated and, if necessary, resolved. The American Society of Anesthesiologists educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all American Society of Anesthesiologists education activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
 
Glenn Murphy, M.D. has reported receiving honoraria from Merck. J. Ross Renew, M.D. has received funded research from Merck. All other faculty, planners, and staff have reported no relevant financial relationships with commercial interests.
Internet connection, web browser version must have been released within the last three years.
Managing the Risks Associated with Postoperative Residual Neuromuscular Blockade to Improve the Patient Experience
  • List Price: Free